HTMC0435 and Temozolomide in Treating Patients With Small Cell Lung Cancer
A Phase 1b/2, Dose-finding and Expansion Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HTMC0435 With Temozolomide in Patients With Small Cell Lung Cancer
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Contact
Study Contact
- Name: Jun Li
- Phone Number: +86-21-64311017
- Email: clinical_trial@hllife.com.cn
Study Locations
-
-
-
Hangzhou, China
- Recruiting
- Zhejiang Cancer Hospital
-
Nanjing, China
- Recruiting
- Jiangsu Province Hospital of Chinese Medicine
-
Zhengzhou, China
- Recruiting
- Henan Cancer Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Male or female, age ≥18 and <75 years old
- Patients with histologically or cytologically confirmed recurrent or progressive extensive-stage SCLC, who have previously received at least first-line and no more than second-line treatments (HRR mutations are preferred)
- [Only applicable to phase II part] At least one measurable lesion according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1)
- Eastern Cooperative Oncology Group (ECOG) performance status of 0~1
- Expected survival period ≥3 months
- Prior to the enrollment, no serious hematopoietic abnormality, and generally normal function of heart, lung, liver and kidney
- Understand and sign the informed consent form (ICF) voluntarily. Be willing and able to complete routine visits, treatment plans, laboratory examinations and other procedures.
Exclusion Criteria:
- Prior treatment with any poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitor
- Prior temozolomide treatment interruption caused by toxicity
- Received treatment with chemotherapy, radiation, biotherapy, endocrine therapy, immunotherapy, or other anti-tumor therapy ≤4 weeks prior to the first dose of HTMC0435
- Any unrecovered AE of prior therapy ≥CTCAE 5.0 Grade 1 (except for toxicity that the investigators judged to have no safety risks, such as alopecia)
- Currently suffering from interstitial lung disease ≥CTCAE Grade 2
- Major surgery (excluding needle biopsy) within 4 weeks before the first dose of HTMC0435
- Past surgical history or severe gastrointestinal diseases that the investigator believes may affect the absorption, distribution or metabolism of the study drug, such as dysphagia, active gastric ulcer, ulcerative colitis, Crohn's disease, ileus, etc.
- History of severe cardiovascular and cerebrovascular diseases
- Received CYP3A4 potent inhibitors or inducers within 7 days before the first dose of HTMC0435 or need to use these medications during the study
- Symptomatic brain metastases or meningeal metastases. Patients with these metastases who have received related treatment need to meet the following conditions before they can be enrolled: no radiographic evidence of progression ≥ 4 weeks after the end of treatment; completion of treatment ≥ 28 days before the first dose; no need for systemic corticosteroids treatment (>10 mg/day prednisone or equivalent dose) within 14 days before the first dose of HTMC0435
- Active infectious diseases which need systemic anti-infection treatment
- Hepatitis B surface antigen (HBsAg) positive with hepatitis B virus (HBV) -DNA >1000 copies/mL or >200 IU/mL; hepatitis C virus antibody (HCV-Ab) positive
- Human immunodeficiency virus antibody (HIV-Ab) positive
- Previous or current diagnosis of myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML)
- Women who are pregnant or breastfeeding; women/men who are planning to have a child; women/men who refuse to use medically approved contraceptive measures for contraception during the study treatment and within 6 months after the end of the study
- Serious psychological or mental abnormalities that may affect compliance of patients in this study
- Current alcohol or drug abusers
- Judgment by the investigator that the patient is not suitable for this study due to other conditions
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Phase 1b
Escalating doses of HTMC0435 and Temozolomide
|
Oral administration.
Oral administration.
|
|
Experimental: Phase 2
Recommended phase 2 dose (RP2D) of HTMC0435 and Temozolomide
|
Oral administration.
Oral administration.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Dose-limiting toxicities (DLT) of HTMC0435 combined with Temozolomide
Time Frame: Cycle 1 Day 1 to Cycle 1 Day 21
|
Cycle 1 Day 1 to Cycle 1 Day 21
|
|
Adverse events (AE) of HTMC0435 combined with Temozolomide
Time Frame: Through study completion, an average of 6 months
|
Through study completion, an average of 6 months
|
|
Maximum tolerable dose (MTD) and RP2D of HTMC0435 combined with Temozolomide
Time Frame: Through study completion, an average of 6 months
|
Through study completion, an average of 6 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Pharmacokinetic measures - the area under the concentration-time curve from dosing (time 0) to time infinity (AUC 0-inf)
Time Frame: Cycle 1 Day 1 to Cycle 1 Day 9
|
Cycle 1 Day 1 to Cycle 1 Day 9
|
|
Pharmacokinetic measures - the area under the concentration-time curve from dosing (time 0) to time t (AUC 0-t)
Time Frame: Cycle 1 Day 1 to Cycle 1 Day 9
|
Cycle 1 Day 1 to Cycle 1 Day 9
|
|
Pharmacokinetic measures - apparent clearance rate (CLz/F)
Time Frame: Cycle 1 Day 1 to Cycle 1 Day 9
|
Cycle 1 Day 1 to Cycle 1 Day 9
|
|
Pharmacokinetic measures - maximum plasma concentrations (Cmax)
Time Frame: Cycle 1 Day 1 to Cycle 1 Day 9
|
Cycle 1 Day 1 to Cycle 1 Day 9
|
|
Pharmacokinetic measures - time to reach Cmax (Tmax)
Time Frame: Cycle 1 Day 1 to Cycle 1 Day 9
|
Cycle 1 Day 1 to Cycle 1 Day 9
|
|
Pharmacokinetic measures - trough concentrations at steady state (Css, min)
Time Frame: Cycle 1 Day 1 to Cycle 1 Day 9
|
Cycle 1 Day 1 to Cycle 1 Day 9
|
|
Pharmacokinetic measures - peak concentrations at steady state (Css, max)
Time Frame: Cycle 1 Day 1 to Cycle 1 Day 9
|
Cycle 1 Day 1 to Cycle 1 Day 9
|
|
Pharmacokinetic measures - accumulation ratio (Rac)
Time Frame: Cycle 1 Day 1 to Cycle 1 Day 9
|
Cycle 1 Day 1 to Cycle 1 Day 9
|
|
Pharmacokinetic measures - terminal plasma half-life (T1/2)
Time Frame: Cycle 1 Day 1 to Cycle 1 Day 9
|
Cycle 1 Day 1 to Cycle 1 Day 9
|
|
Pharmacokinetic measures - apparent volume of distribution during terminal phase (Vz/F)
Time Frame: Cycle 1 Day 1 to Cycle 1 Day 9
|
Cycle 1 Day 1 to Cycle 1 Day 9
|
|
Objective response rate (ORR) by RECIST v1.1
Time Frame: Through study completion, an average of 6 months
|
Through study completion, an average of 6 months
|
|
Disease control rate (DCR) by RECIST v1.1
Time Frame: Through study completion, an average of 6 months
|
Through study completion, an average of 6 months
|
|
Progression-free survival (PFS) by RECIST v1.1
Time Frame: Through study completion, an average of 6 months
|
Through study completion, an average of 6 months
|
|
Duration of response (DOR) by RECIST v1.1
Time Frame: Through study completion, an average of 6 months
|
Through study completion, an average of 6 months
|
|
Overall survival (OS) by RECIST v1.1
Time Frame: Through study completion, an average of 6 months
|
Through study completion, an average of 6 months
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Changes in neuron-specific enolase (NSE) level from baseline
Time Frame: Through study completion, an average of 6 months
|
Through study completion, an average of 6 months
|
|
Changes in pro-gastrin-releasing peptide (PROGRP) level from baseline
Time Frame: Through study completion, an average of 6 months
|
Through study completion, an average of 6 months
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: yun fan, MD, Zhejiang Cancer Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Respiratory Tract Diseases
- Neoplasms
- Lung Diseases
- Neoplasms by Site
- Respiratory Tract Neoplasms
- Thoracic Neoplasms
- Carcinoma, Bronchogenic
- Bronchial Neoplasms
- Lung Neoplasms
- Small Cell Lung Carcinoma
- Molecular Mechanisms of Pharmacological Action
- Antineoplastic Agents
- Antineoplastic Agents, Alkylating
- Alkylating Agents
- Temozolomide
Other Study ID Numbers
Other Study ID Numbers
- HLND-01-TMZ-Ib/II-01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.